GVR Report cover Heparin Market Size, Share & Trends Report

Heparin Market Size, Share & Trends Analysis Report By Type (Low Molecular Weight, Ultra-low Molecule Weight), By Route of Administration, By Application Form, By End Use, And Segment Forecasts, 2020 - 2026

  • Report ID: GVR-3-68038-154-2
  • Number of Pages: 80
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2018
  • Industry: Healthcare

Report Overview

The global heparin market size was estimated at USD 6.49 billion in 2019 and is projected to expand at a CAGR of 1.6%. Increasing number of accidents and surgeries is expected to be a key driver for the growth. Increasing incidence of venous thromboembolism and cardiovascular disorders is expected to fuel the market growth over the forecast period.

According to the data published in the Centers for Disease Control and Prevention (CDC) in 2018, around 900,000 people in U.S. are affected by deep vein thrombosis and pulmonary embolism each year. This factor is projected to propel the regional demand in the forthcoming years.

U.S. heparin market

Some biopharmaceutical companies are financing resources for the development of new drugs. Organizations such as the CDC and the National Institutes of Health (NIH) are undertaking initiatives for increasing awareness levels through programs that aim preventing thrombosis-associated complications in initial stages.

High demand for anticoagulants is anticipated to boost the overall heparin market. Furthermore, high healthcare expenditures and patient awareness levels are some of the key factors anticipated to accelerate the market over the forecast period.

Heparin Market Trends

Increasing prevalence of chronic diseases such as cardiovascular disorders, deep vein thrombosis, pulmonary embolism, and renal diseases is considered to be one of the major factors driving the overall market. According to CDC in 2022, over 900,000 suffer from pulmonary embolism or deep vein thrombosis each year, resulting in the death of 10-30% of individuals within a month of diagnosis. Furthermore, recurrence is prevalent in nearly one-third of the individuals. Moreover, as per the British Medical Journal in 2022, infections such as COVID-19 increase the risk of developing deep vein thrombosis by five folds. Thereby, creating a lucrative market opportunity.

Increasing demand for blood components, transfusion of blood, & plasma derivatives in the treatment of infectious diseases & surgical procedures, and rising survival rates are among the high-impact rendering drivers for growth of heparin market during the forecast period. Blood transfusion is considered crucial for treating various diseases, thus the rate of blood transfusion has increased significantly in the past few years.

Rising incidence of immunological diseases, thrombosis, and hemostasis is increasing the demand for therapeutic plasma proteins. Manufacturing of these plasma proteins has increased the demand for purified plasma, which is expected to drive the heparin market over the forecast period. Plasma may contain as many as 45,000 different proteins from more than 500 genes. The demand for source plasma is expected to increase in the next few years with increase in the number of market players manufacturing plasma-derived proteins and biosimilars.

The number of people aged 60 and above has substantially increased in the recent years in most regions and this growth is expected to accelerate in the following years. According to World Population Aging Report by United Nations, the number of elderly people aged 80 and over is projected to triple by 2050 and will reach 434 million.

Emerging oral anticoagulants are expected to restrain the growth of heparin market due to increasing patient compliance pertaining to route of administration of products. In addition, launch of novel oral anticoagulants, such as Eliquis, Xarelto, and Pradaxa, is expected to hamper the growth of the overall market. Oral anticoagulants prevent stroke and also lower the incidence of major bleeding with minor drug & food interactions, thus offering more opportunities in the heparin market over the forecast period. However, heparin’s use in interventional and surgical operations lacks alternatives.

Increasing prevalence of infectious and blood transmissible diseases is a critical factor that may restrain the market growth. Blood to be transfused needs to be safe and free from syphilis, Human Immunodeficiency Virus (HIV), hepatitis, and other infectious disease particles. Donors need to be checked before blood donation. Systems for the determination of antigens on blood cells and the antibodies in serum should be robust and accurate. However, according to WHO, over 99.8% of blood donations are screened in higher-income and higher-middle-income nations. This rate is over 83% in lower-middle and lower-income nations. Thus, this factor is anticipated to lose its impact over time.

Type Insights

Based on type, the market is segmented into low molecular weight, ultra-low molecular weight, and unfractionated heparin. Low molecular weight segment held the largest heparin market share in 2018 owing to more predictable anticoagulant effect of the product.

In addition, according to a study published in NEJM Journal Watch, low incidence of heparin induced thrombocytopenia contribute towards the segment growth. Ultra-low molecular weight heparin is expected to be the fastest growing segment over the forecast period owing to commercialization of products with improved pharmacological effects.

Route of Administration Insights

On the basis of route of administration, the market is bifurcated into intravenous and subcutaneous. The subcutaneous segment led the market in 2018 and is expected to be the fastest growing segment with a lucrative CAGR over the coming years due to less cost associated with hospitalization.

Furthermore, on the basis of patient’s perspective, subcutaneous route is more preferred owing to ease of administration, rising preference for home care and reduced duration of treatment. Moreover, the associated benefits of this route of administration includes low risk of systemic infection and improved quality of life.

Application Insights

Based on the application, the market has been categorized into venous thromboembolism, atrial fibrillation, renal impairment, and coronary artery disease. Among these, coronary artery disease held the largest share in 2018 owing to increasing prevalence and incidence of heart-related disorders.

According to statistics published in the American Heart Association, in 2018, around 92.1 million American adults were suffering from some form of cardiovascular disease. In addition, around 1 in every 3 deaths are caused by cardiovascular disease in the U.S. accounting for around 2,300 deaths per day.

Venous thromboembolism (VTE) is expected to be the fastest growing segment over the forecast period. Venous thromboembolism is segmented into pulmonary embolism (PE) and deep vein thrombosis (DVT). Increasing awareness of thrombosis is one of the major factors driving the segment growth. For instance, introduction of online portal by International Society on Thrombosis and Haemostasis, Inc. is expected to improve the awareness of thrombosis amongst patients.

Moreover, increasing mortality rates of venous thromboembolism is anticipated to contribute towards the segment growth. According to the facts published in the International Society on Thrombosis and Haemostasis, Inc., around 10 million cases of VTE is recorded globally every year and around 544,000 VTE related deaths are observed every year in Europe.

End Use Insights

On the basis of end use, the market is segmented into inpatients and outpatients. Outpatient was the largest segment in 2018 and is estimated to witness the fastest CAGR of 2.4% over the forecast period. Increasing preference of subcutaneous route of administration among the patients is a major factor responsible for market growth.

Global heparin market

In addition, outpatient hospital cost is less as compared inpatient hospital cost. Moreover, according to various studies published in the NCBI, outpatient therapy was associated with lower rate of recurrent venous thromboembolism.

Regional Insights

North America held the largest share of the heparin market in 2021. Increasing sports injuries in this region is one of the major factors driving its overall market. As per the Harvard School of Public Health, by 2030, roughly half of the U.S population will be obese. As per Obesity Canada in 2019, the obesity rate in Canada is projected to rise. Related health issues, such as blood clots and stroke, are also expected to increase in prevalence, further contributing to market growth. According to the Center for Disease Control (CDC), in 2022, 6,59,000 deaths occurred due to heart diseases in the U.S.

The market in Australia is driven by the growing prevalence of diseases such as DVT, PE, & cardiovascular disorders, and proactive government initiatives. For instance, the Australian Government of Health offers a list of heparin manufacturers with discounted prices. In addition, the local presence of key players, such as Hospira Pty Limited and Pfizer Australia Pty Ltd., is considered to be a major factor driving the market.

According to a study carried out by the Royal College of Nursing, it was observed that Venous Thromboembolism (VTE) is a major cause of death in the UK. Annually, about 25,000 people in the UK are anticipated to die from VTE associated with hospitalization. Vitae, National Clinical Guideline Centre for Acute and Chronic Conditions (previously known as the National Collaborating Centre for Acute Care), and Thrombosis UK are organizations in the UK that promote awareness and care regarding VTE.

Key Companies & Market Share Insights

The key players are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd.

Mostly, the companies are involved in implementing strategies such as mergers and acquisitions, collaborations, and product development to increase their market share. For instance, in 2018, Fresenius Kabi launched heparin sodium in ready-to-administer non DEHP freeflex bags, thus expanding the company’s critical care portfolio.

Heparin Market Report Scope

Report Attribute

Details

Market size value in 2020

USD 7.0 billion

Revenue forecast in 2026

USD 7.4 billion

Growth Rate

CAGR of 1.6% from 2020 to 2026

Base year for estimation

2019

Historical data

2014 - 2018

Forecast period

2020 - 2026

Quantitative units

Revenue in USD Million & CAGR from 2020 to 2026

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Type, route of administration, application, end use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; U.K.; Germany; France; Italy; Spain; Russia; Mexico; Brazil; Argentina; Japan; China; India; South Korea; Australia; Singapore; South Africa; UAE; Saudi Arabia

Key companies profiled

GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; Teva Pharmaceutical Industries Ltd

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global heparin market report on the basis of type, route of administration, application, end use, and region:

  • Type Outlook (Revenue, USD Million, 2014 - 2026)

    • Low Molecular Weight Heparin

    • Ultra-low Molecular Weight Heparin

    • Unfractionated Heparin

  • Route of Administration Outlook (Revenue, USD Million, 2014 - 2026)

    • Intravenous

    • Subcutaneous

  • Application Outlook (Revenue, USD Million, 2014 - 2026)

    • Venous Thromboembolism

    • Atrial Fibrillation

    • Renal Impairment

    • Coronary Artery Disease

    • Others

  • End Use Outlook (Revenue, USD Million, 2014 - 2026)

    • Outpatient

    • Inpatient

  • Regional Outlook (Revenue, USD Million, 2014 - 2026)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • France

      • U.K.

      • Italy

      • Spain

      • Russia

    • Asia Pacific

      • Japan

      • China

      • India

      • South Korea

      • Australia

      • Singapore

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East & Africa

      • South Africa

      • Saudi Arabia

      • UAE

Frequently Asked Questions About This Report

pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.